explore -WSS

explore

author：comprehensive 2025-09-06 04:51:34 - browse：9

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Colorectal cancer study finds potential in overlooked immune cell

explore

WSS

Stroke deaths set to near 10 million globally by 2050

Disclosing genetic information: not as worrisome as once feared

Liquid biopsy for lung cancer is launched by Delfi

FDA authorizes Novavax’s updated Covid

AI can decode, harness the power of the humane immune system

3 questions for the future of Biden's cancer moonshot

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

Physician executives need more than on

Cancer drug shortages should be causing more outrage

Was Amgen transparent enough on FDA's concern on cancer drug?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

When women are denied an abortion, their children fare worse than peers

United colonoscopy coverage change 'may cost lives,' doctors say

Histogen: Failed biotech offers rare public look inside

Peter Hotez and the public health issue of online harassment

3 hurdles to bringing medical devices to the U.S. market

focus

Weight bias in eating disorder treatment complicated by new weight loss drugs

Why we need to separate burnout from moral injury in health care

STAT's guide to the next generation of CAR

#NeedHerScience: shining a light on gender disparities in medicine

The strategy behind pharma's lawsuits over drug pricing reform

3 hurdles to bringing medical devices to the U.S. market

entertainment

explore

hotspot

focus